ReviewClinical rheumatology2025
From endotypes to therapeutic targets: exploring the potential of precision treat-to-target approaches in primary Sjögren's disease.
Review in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSjögren's disease (SjD) is a clinically and biologically heterogeneous autoimmune disease with a wide range of glandular and systemic manifestations. Although significant progress has been made in elucidating its pathogenesis, current management remains predominantly symptomatic, and disease-modifying therapies are still lacking. The substantial heterogeneity of SjD poses major challenges for clinical trial design, treatment stratification, and the development of evidence-based guidelines.
objectiveThis review summarizes recent advances in clinical and molecular endotyping of SjD and explores how these insights can inform the development of precision treat-to-target (T2T) strategies tailored to specific patient subgroups. CONTENT: We review the evolving landscape of SjD stratification, encompassing symptom-based clinical phenotypes, immunologic and transcriptomic endotypes, and cross-disease immune signatures. We highlight how distinct endotypes are associated with differential therapeutic responses, guiding the application of B cell-targeted therapies, interferon (IFN) pathway inhibitors, immune regulatory interventions, and metabolic modulators. The potential of dynamic monitoring approaches-including composite clinical endpoints, multi-omics biomarkers, and artificial intelligence-assisted stratification-is also discussed as a foundation for implementing precision T2T strategies in SjD. Finally, key challenges and future directions for clinical translation are addressed.
conclusionPrecision T2T strategies, grounded in comprehensive clinical and molecular stratification, have the potential to improve individualized management of SjD. Future research should focus on validating dynamic monitoring tools and optimizing biomarker-guided treatment pathways to advance personalized care in this complex disease.
Indexed as
Identifiers
41108351What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.